Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guimarães, F.S.
Right arrow Articles by Graeff, F.G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Guimarães, F.S.
Right arrow Articles by Graeff, F.G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Psychopharmacology, Vol. 1, No. 3, 184-192 (1987)
DOI: 10.1177/026988118700100305

Effect of chlorimipramine and maprotiline on experimental anxiety in humans

F.S. Guimarães

Department of Pharmacology Campus of the University of São Paulo, BR 14049, Ribeirão Preto, SP, Brazil

A.W. Zuardi

Departmtent of Neuropsychiatry Campus of the University of São Paulo, BR 14049, Ribeirão Preto, SP, Brazil

F.G. Graeff

FMRP and Laboratory of Psychobiology Campus of the University of São Paulo, BR 14049, Ribeirão Preto, SP, Brazil

In order to assess the role played by serotonin (5-HT) and noradrenaline in anxiety, four groups of healthy volunteers were given 25 mg of the selective inhibitor of 5-HT uptake chlorimipramine, 50 mg of the selective inhibitor of noradrenaline uptake maprotiline, 1 mg of the benzodiazepine anxiolytic lorazepam or placebo, and submitted to a simulated public speaking (SPS) test, consisting of speaking in front of a videocamera. Subjective anxiety was evaluated by the visual analog mood scale (VAMS) of Norris as well as by the state-trait anxiety inventory (STAI) of Spielberger. Chlorimipramine enhanced SPS-induced anxiety, whereas maprotiline and lorazepam reduced anxiety during as well as outside the test period. Mental and physical sedation (VAMS) were increased by either maprotiline or lorazepam. In a scale of bodily symptoms, chlorimipramine tended to increase muscle tension, agitation and palpitation, whereas maprotiline caused lethargy. The rise in blood pressure induced by the SPS procedure outlasted the period of stress in the group treated with chlorimipramine. In contrast, the SPS-induced increase in heart rate was enhanced by lorazepam. Chlor imipramine and maprotiline reduced salivation to the same extent. Pupillary diameter, however, was significantly increased by chlorimipramine alone. It may be tentatively sug gested that the proanxiogenic effect of chlorimipramine is related to changes in central 5-HT neurotransmission while the anxiolytic effect of maprotiline is associated with alteration of noradrenergic mechanisms. Increased peripheral sympathetic tone may also contribute to the proanxiety action of chlorimipramine.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
A.W. Zuardi, R.A. Cosme, F.G. Graeff, and F.S. Guimaraes
Effects of ipsapirone and cannabidiol on human experimental anxiety
J Psychopharmacol, January 1, 1993; 7(1_suppl): 82 - 88.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
J. F. W. Deakin and F. G. Graeff
5-HT and mechanisms of defence
J Psychopharmacol, January 1, 1991; 5(4): 305 - 315.
[PDF]